London, United Kingdom
Bastion Therapeutics, founded in 2018 and headquartered in the United Kingdom, is a preclinical stage biotech company with a compelling vision: Creating a future where inflammatory disorders are curable. Focused on developing innovative Treg cell therapies, the company targets the vast unmet clinical needs of inflammatory disorders.
The core of their potential lies in their proprietary GRIT™ platform technology, which engineers Tregs to effectively modulate the immune system while addressing limitations of previous Treg therapies. This positions Bastion Therapeutics as a frontrunner in delivering therapies that are efficacious, durable, and safe.
Recently, Bastion Therapeutics secured an $840K Early VC investment in September 2023, with backing from prominent investors like Science, NG Bio, Pioneer Group, and Wren Capital. This investment underscores confidence in their innovative approach and potential to revolutionize treatment for inflammatory conditions.
